Latest news
Debiopharm and Yale announce an exclusive license agreement for the development and commercialization of Debio 1036, a first-in-class inhibitor for…
The Debiopharm Group and Marina Biotech Partner to Develop and Commercialise RNAi-based Therapies for the Treatment of Bladder Cancer
Diagnoplex Closes an Extension of Its Series A Financing with a substantial Investment by Debiopharm Group™
Frost & Sullivan Presents Debiopharm Group™ with “European Biopharmaceuticals Company of the Year Award”
Abionic wins the ‘Prix Debiopharm Valais pour les Sciences de la Vie’ for its innovative biomedical device for diagnostic testing
Inauguration du “Debiopharm Laboratory”: Debiopharm Group équipe la Haute Ecole Spécialisée – SO Valais d’un laboratoire peptidique de pointe
The Japanese Cancer Association and Debiopharm Group™present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for their outstanding oncology…